18
Feb 2026
How GLP-1 drugs affect the body beyond weight loss and glucose control
This review evaluates the safety profile of glucagon-like peptide-1 receptor agonists and related incretin therapies used for obesity and type 2 diabetes. It highlights common gastrointestinal effects, rare but debated risks, and areas where further long-term safety data are still needed.